At Novonesis, we believe solutions rooted in biology are key to tackling the challenges our world faces.
We develop and sell enzymes and functional proteins as well as microorganisms such as cultures, probiotics, postbiotics and yeast. These are some of our planet's tiniest, yet mightiest agents of change. When we leverage their power with our technology to solve problems, we create what we call biosolutions. And they’re revolutionizing the way we all produce, consume and live.
Today we are 10,000 people worldwide with expertise that spans more than 30 industries. All around the world our biosolutions are already helping companies balance their business needs with those of our planet.
The time for biosolutions is now. And by working closely with our partners and customers, we will continue to challenge conventional thinking and transform business with biology. Together we will create the change our world needs.
Chr. Hansen and Novozymes joined forces in January 2024 to create Novonesis, positioning it as a leading global biosolutions partner. The company aims to leverage the power of biology to drive positive change. By combining the expertise of both legacy companies, Novonesis is poised to contribute to better business practices, healthier lives, and a more sustainable planet.
Established in 1978, Biocon is India's premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical enterprise, focused on healthcare. In 2007, Biocon made a strategic decision to divest its historic enzymes business to Novozymes A/S of Denmark. Biocon now strategically focuses its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development with this divestment, the company mission is to ‘Develop novel & affordable Biotherapeutics for global markets’.
Biocon Limited and its two subsidiary companies, Syngene International Limited and Clinigene International Limited form a fully integrated biotechnology enterprise specializing in biopharmaceuticals, custom research and clinical research. Biocon's integrated business approach has enabled the company to establish a significant presence in the global biopharmaceutical market via its product offerings and customised, high value solutions at any stage in the lifecycle of a drug-from discovery to market. Biocon’s vision is to be an integrated biopharmaceutical enterprise of global distinction.
The company applies its proprietary fermentation technologies to make effective and innovative biomolecules in diabetology, oncology, cardiology and other therapeutic segments. Biocon's products in the biopharmaceutical category include: anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-oxidants, biologicals, cholesterol-lowering agents, haemostatic agents, hepatoprotective agents, immunosuppressants, nutraceuticals and orthopaedic agents.
Amano Enzyme is a global biotechnology enterprise specializing in the production of specialty microbial enzymes for food, pharmaceuticals, and clinical diagnostics, founded in Japan in 1899 with modern operations established in 1948. Manufacturers and producers of enzyme solutions intended for the improvement of human life as a key attribute and principle of biotechnology. The company provides microbial enzymes for food, dietary supplements, industrial, diagnostic, and regenerative medical applications, along with specialty enzymes for food, beverage, dietary supplements, and biotechnology applications. Amano Enzyme offers a comprehensive range of amylases designed specifically for the liquefaction and saccharification steps in cereal-based drinks like oat and rice beverages. Gluten-free and derived from non-GM microorganisms (Non-genetically modified enzymes), our enzymes ensure optimal performance and product consistency.
IncepBio is an ISO 9001:2015 accredited pharmaceutical engineering and compliance solutions company supporting clients in: